Search Results
You are looking at 1 - 2 of 2 items for
- Author: E. Spanos x
- Refine by access: All content x
Search for other papers by M. Pizzi in
Google Scholar
PubMed
Search for other papers by S. Rubessa in
Google Scholar
PubMed
Search for other papers by E. Simonazzi in
Google Scholar
PubMed
Search for other papers by V. Zanagnolo in
Google Scholar
PubMed
Search for other papers by L. Falsetti in
Google Scholar
PubMed
Search for other papers by M. Memo in
Google Scholar
PubMed
Search for other papers by P. F. Spano in
Google Scholar
PubMed
ABSTRACT
Vasoactive intestinal peptide (VIP) is a prolactin-releasing hormone which is involved in the multifactorial modulation of prolactin secretion in mammals. Intravenous injection of VIP (1 μg/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure. The same treatment to menopausal women caused similar cardiovascular effects but did not modify plasma prolactin levels. In contrast, TRH (200 μg, i.v.) induced a significant increase in plasma prolactin levels in both fertile and menopausal women. The relevance of oestrogens in affecting VIP-stimulated prolactin secretion was evaluated in vitro by measuring prolactin release from pituitary cells of control and ovariectomized rats. The sensitivity of rat mammotrophs to VIP, but not to TRH, was completely suppressed 3 or 4 weeks after ovariectomy. Furthermore, implantation of rats with a silastic capsule containing oestradiol-17β during ovariectomy, preserved the cell responsiveness to VIP. The prolactin-releasing property of VIP was also restored when pituitary cells from ovariectomized rats were cultured for 3 days in the presence of 10 nmol oestradiol-17β/l before being used for prolactin release experiments. The present study shows that the ability of prolactin-secreting cells to respond to the stimulatory action of VIP requires high levels of circulating oestrogens, both in man and rats.
Journal of Endocrinology (1992) 132, 311–316
Search for other papers by C. J. Robinson in
Google Scholar
PubMed
Search for other papers by E. Spanos in
Google Scholar
PubMed
Search for other papers by M. F. James in
Google Scholar
PubMed
Search for other papers by J. W. Pike in
Google Scholar
PubMed
Search for other papers by M. R. Haussler in
Google Scholar
PubMed
Search for other papers by A. M. Makeen in
Google Scholar
PubMed
Search for other papers by C. J. Hillyard in
Google Scholar
PubMed
Search for other papers by I. MacIntyre in
Google Scholar
PubMed
Intestinal calcium absorption and plasma levels of 1,25-dihydroxycholecalciferol (1,25(OH)2D3) were measured in lactating and non-lactating rats and the effects of bromocriptine and exogenous prolactin treatment were evaluated. In lactating rats calcium absorption and plasma levels of parathyroid hormone, 1,25(OH)2D3 and alkaline phosphatase activity were significantly increased. Bromocriptine treatment significantly reduced the enhanced calcium absorption and levels of plasma 1,25(OH)2D3 and alkaline phosphatase but had no significant effect on plasma levels of parathyroid hormone. Prolactin administered with bromocriptine to lactating animals prevented all the changes observed with bromocriptine treatment alone. It was concluded that the increased plasma levels of prolactin during lactation lead to high plasma levels of 1,25(OH)2D3 which are responsible for the enhanced intestinal calcium absorption.
